These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 22480822

  • 1. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders.
    Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L.
    Fertil Steril; 2012 Jun; 97(6):1316-20. PubMed ID: 22480822
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.
    O'Neill KE, Senapati S, Maina I, Gracia C, Dokras A.
    J Assist Reprod Genet; 2016 Sep; 33(9):1175-84. PubMed ID: 27349252
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Ovulation triggering with hCG alone, GnRH agonist alone or in combination? A randomized controlled trial in advanced-age women undergoing IVF/ICSI cycles.
    Zhou C, Yang X, Wang Y, Xi J, Pan H, Wang M, Zhou Y, Xiao Y.
    Hum Reprod; 2022 Jul 30; 37(8):1795-1805. PubMed ID: 35595223
    [Abstract] [Full Text] [Related]

  • 7. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C.
    Fertil Steril; 2008 Jan 30; 89(1):84-91. PubMed ID: 17462639
    [Abstract] [Full Text] [Related]

  • 8. Reproductive outcomes after a single dose of gonadotropin-releasing hormone agonist compared with human chorionic gonadotropin for the induction of final oocyte maturation in hyper-responder women aged 35-40 years.
    Tannus S, Turki R, Cohen Y, Son WY, Shavit T, Dahan MH.
    Fertil Steril; 2017 Jun 30; 107(6):1323-1328.e2. PubMed ID: 28501366
    [Abstract] [Full Text] [Related]

  • 9. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates.
    Radesic B, Tremellen K.
    Hum Reprod; 2011 Dec 30; 26(12):3437-42. PubMed ID: 21997895
    [Abstract] [Full Text] [Related]

  • 10. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C.
    Fertil Steril; 2010 Feb 30; 93(3):847-54. PubMed ID: 19200959
    [Abstract] [Full Text] [Related]

  • 11. GnRH agonist versus HCG triggering in different IVF/ICSI cycles of same patients: a retrospective study.
    Yılmaz N, Ceran MU, Ugurlu EN, Gülerman HC, Engin Ustun Y.
    J Obstet Gynaecol; 2020 Aug 30; 40(6):837-842. PubMed ID: 31791167
    [Abstract] [Full Text] [Related]

  • 12. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates.
    Griffin D, Feinn R, Engmann L, Nulsen J, Budinetz T, Benadiva C.
    Fertil Steril; 2014 Aug 30; 102(2):405-9. PubMed ID: 24842671
    [Abstract] [Full Text] [Related]

  • 13. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.
    Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S.
    Fertil Steril; 2011 May 30; 95(6):2029-33, 2033.e1. PubMed ID: 21371705
    [Abstract] [Full Text] [Related]

  • 14. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
    Orvieto R.
    J Ovarian Res; 2015 Nov 04; 8():69. PubMed ID: 26536862
    [Abstract] [Full Text] [Related]

  • 15. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
    Engmann LL, Maslow BS, Kaye LA, Griffin DW, DiLuigi AJ, Schmidt DW, Grow DR, Nulsen JC, Benadiva CA.
    J Ovarian Res; 2019 Jan 26; 12(1):8. PubMed ID: 30684970
    [Abstract] [Full Text] [Related]

  • 16. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
    Bodri D, Guillén JJ, Galindo A, Mataró D, Pujol A, Coll O.
    Fertil Steril; 2009 Feb 26; 91(2):365-71. PubMed ID: 18367175
    [Abstract] [Full Text] [Related]

  • 17. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S, Blockeel C, Tremellen KP, Fleming R, Tournaye H, Humaidan P, Nelson SM.
    Hum Reprod; 2013 Sep 26; 28(9):2529-36. PubMed ID: 23873146
    [Abstract] [Full Text] [Related]

  • 18. Retrospective comparison of GnRH agonist trigger with HCG trigger in GnRH antagonist cycles in anticipated high-responders.
    Datta AK, Eapen A, Birch H, Kurinchi-Selvan A, Lockwood G.
    Reprod Biomed Online; 2014 Nov 26; 29(5):552-8. PubMed ID: 25246126
    [Abstract] [Full Text] [Related]

  • 19. GnRHa to trigger final oocyte maturation: a time to reconsider.
    Humaidan P, Papanikolaou EG, Tarlatzis BC.
    Hum Reprod; 2009 Oct 26; 24(10):2389-94. PubMed ID: 19608565
    [Abstract] [Full Text] [Related]

  • 20. The benefit of individualized low-dose hCG support for high responders in GnRHa-triggered IVF/ICSI cycles.
    Huang CY, Shieh ML, Li HY.
    J Chin Med Assoc; 2016 Jul 26; 79(7):387-93. PubMed ID: 27147462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.